Evidence map›Paper›PMID 42022515›Full record

ArticleRespirology case reports2026

The Eye Never Lies: When A Lesion Unveils Lung Cancer.

Sivanesan Darshini, Nor Safiqah Sharil, Boon Hau Ng, Xin Yee Chong, Andrea Yu-Lin Ban, Nik Nuratiqah Nik Abeed

Abstract read
In one paragraph

Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sivanesan DarshiniRespiratory Unit, Department of Medicine, Faculty of Medicine, Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia.
Nor Safiqah SharilInternal Medical Unit, Faculty of Medicine and Health Science Universiti Sains Islam Malaysia Nilai Negeri Sembilan Malaysia.ORCID https://orcid.org/0000-0002-1201-9273
Boon Hau NgRespiratory Unit, Department of Medicine, Faculty of Medicine, Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia.ORCID https://orcid.org/0000-0002-0750-3087
Xin Yee ChongOphthalmology Department Hospital Cyberjaya Selangor Malaysia.
Andrea Yu-Lin BanRespiratory Unit, Department of Medicine, Faculty of Medicine, Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia.ORCID https://orcid.org/0000-0003-3788-4789
Nik Nuratiqah Nik AbeedRespiratory Unit, Department of Medicine, Faculty of Medicine, Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia.ORCID https://orcid.org/0000-0002-3283-649X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocular manifestations rarely represent the first sign of systemic malignancy and often pose a diagnostic challenge. While choroidal metastases are more common, iris involvement is uncommon and may be underrecognized. Lung adenocarcinoma, particularly non-small cell subtypes, is a known source of ocular metastases, with iris lesions occasionally preceding systemic symptoms. We report a 70-year-old previously healthy man presenting with one month of left eye blurred vision. Initial examination revealed conjunctival injection and visual acuity of 6/20 without detectable lesions; topical dexamethasone was prescribed. Six weeks later, vision declined to finger counting, and a hypopigmented iris mass (7.0 × 5.7 mm) was identified. A brain MRI revealed a right occipital lesion, and a CECT of the thorax, abdomen, and pelvis showed a left lung mass with bilateral nodules, mediastinal lymphadenopathy, and right iliac metastasis. CT-guided biopsy confirmed stage IV lung adenocarcinoma (TTF-1 and Napsin A positive, PD-L1 TPS 80%, EGFR/ALK/ROS1 negative). Pembrolizumab was initiated; filamentous keratitis developed during therapy, and progression at three months prompted conventional chemotherapy. This case emphasizes the rarity of iris metastasis as the initial presentation of lung adenocarcinoma.

Indexed as

iris metastasislung adenocarcinomapembrolizumab

Identifiers

PMID42022515
PMCPMC13098104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.